Balkan Eda, Bilici Mehmet, Gundogdu Betul, Aksungur Nurhak, Kara Asli, Yasar Ezgi, Dogan Hasan, Ozturk Gurkan
Department of Medical Bıology, Faculty of Medicine, Ataturk University,Erzurum, Turkey.
J BUON. 2020 Jan-Feb;25(1):574-581.
Cancer is the leading cause of death in economically developed countries and the second leading cause of death in developing countries. The relationship between genetic polymorphisms and cancer risk has been extensively researched. In the present study, we evaluated the association between polymorphisms in two DNA repair genes, ERCC2 Lys751Gln (rs13181) and XRCC2 Arg188His (rs3218536) and the risk of colorectal, stomach, HCC, prostate and lung cancer.
This study was planned by the Medical Biology Unit and Department of Internal Medicine, Pathology and Surgical Medicine Sciences of Ataturk University. A total of 40 colon cancer, 40 gastric cancer, 40 hepatocellular carcinoma (HCC), 40 prostate cancer, and 40 lung cancer patients and 40 healthy individuals over 18 years of age were enrolled in the study (Controls). All patients and healthy subjects underwent ERCC2 Lys751Gln rs13181 and XRCC2 Arg188His rs3218536 genotyping. After collection of 10 ml venous blood from the patients, DNA was isolated and single nucleotide polymorphism (SNP) analysis was performed using Roche 480 Real-Time PCR device. Results were analyzed using SPSS version 23.0 software.
There were statistically significant differences in ERCC2 Lys751Gln rs13181 polymorphism variants GG colon and GT in the colon control and GG,TTprostate cancer groups when compared with the control group.. GG variant of XRCC2 Arg188 rs3218536 was higher in the gastric patient group. AG variant of XRCC2 Arg188 rs3218536 was higher in gastric control group Conclusion: The results of the present study demonstrate that ERC22 Lys751Gln polymorphisms may be associated with the development of colon and prostate cancers in the Turkish population. This was a small-scale study, and the results should be corroborated with further research including larger groups of patients with each cancer type and more healthy controls.
癌症是经济发达国家的主要死因,在发展中国家是第二大死因。基因多态性与癌症风险之间的关系已得到广泛研究。在本研究中,我们评估了两个DNA修复基因ERCC2 Lys751Gln(rs13181)和XRCC2 Arg188His(rs3218536)的多态性与结直肠癌、胃癌、肝癌、前列腺癌和肺癌风险之间的关联。
本研究由阿塔图尔克大学医学生物学单位以及内科、病理学和外科学系规划。共有40例结肠癌患者、40例胃癌患者、40例肝细胞癌(HCC)患者、40例前列腺癌患者、40例肺癌患者以及40名18岁以上的健康个体(对照组)纳入本研究。所有患者和健康受试者均接受了ERCC2 Lys751Gln rs13181和XRCC2 Arg188His rs3218536基因分型。从患者采集10ml静脉血后,分离DNA,并使用罗氏480实时PCR设备进行单核苷酸多态性(SNP)分析。结果使用SPSS 23.0软件进行分析。
与对照组相比,ERCC2 Lys751Gln rs13181多态性变体GG在结肠癌对照组和GG、TT前列腺癌组中存在统计学显著差异。XRCC2 Arg188 rs3218536的GG变体在胃癌患者组中更高。XRCC2 Arg188 rs3218536的AG变体在胃癌对照组中更高。结论:本研究结果表明,ERCC2 Lys751Gln多态性可能与土耳其人群中结肠癌和前列腺癌的发生有关。这是一项小规模研究,结果应通过进一步研究进行证实,包括纳入更多每种癌症类型的患者群体和更多健康对照。